Company intelligence / Profile preview

Notify Therapeutics

Copenhagen, Denmarknotifytherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Notify Therapeutics has demonstrated proof-of-concept efficacy in rodent models and ex-vivo patient samples, showing significant increases in successful pregnancies. Preliminary toxicology studies indicate no safety concerns. The company is preparing its lead candidate for clinical trials targeting non-hormonal activation of dormant ovarian follicles.

Therapeutic areas: Women's Health
Modalities: Small molecules
Industry: Biotech

Partnerships

BioInnovation Institute Foundation’s Creation House incubator program

Beyond the preview

Go deeper on Notify Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Notify Therapeutics.

Explore the full profile